IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

This is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluating the efficacy and safety of IBI306 monotherapy in Chinese Paricipants with non-familial hypercholesterolemia and mixed hyperlipidemia. Approximately 198 participants were planned to be enrolled in the study. The entire study period includes a screening period of no more than 2 weeks, a run-in period of 4 weeks, a double-blind treatment period of 12 weeks, and a safety follow-up period after the last treatment. Participants were required to maintain a stable and healthy lifestyle throughout the trial.

NCT Number	NCT07473960
Lead Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions	Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Enrollment	198 participants
Start Date	2026-04-01
Primary Completion	2026-09-06 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-14